XENON PHARMACEUTICALS INC. (XENE)

Every figure this model derived for XENE, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,007,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 930,686,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 945,868,000 AssetsCurrent 2026-06-30
current liabilities 45,009,000 LiabilitiesCurrent 2026-06-30
equity 1,242,396,000 StockholdersEquity 2026-06-30
ocf -337,520,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 61,446,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up XENE on one particular measure came for.

RatioValue
current ratio21.02
current ratio reported21.02
deferred revenue growth-70.43
dilution pct1.75
growth cv1.84
revenue growth-100.0
revenue growth per share-100.0
roic-111.92

What to be careful about

What this model itself distrusts about XENE's figures. Written by the derivation as it ran, not added afterwards.